Introduction
Toll-like receptors (TLRs) have emerged as sensors that can detect a variety of invading pathogens and malignant cells, thus serving as a first line of defense against infectious diseases and cancer. Ligand recognition by TLRs triggers dendritic cells (DCs) and other antigen-presenting cells to secrete proinflammatory cytokines and to promote DC maturation programs for the induction of adaptive immune responses (Iwasaki and Medzhitov, 2004; Takeda and Akira, 2005) . At least 12 TLRs have been identified in humans and mice. These type-1 integral membrane glycoproteins are characterized by extracellular domains containing variable numbers of leucine-rich repeat (LRR) motifs and a cytoplasmic Toll/interleukin (IL)-1R homology domain. They recognize a limited but highly conserved set of molecular structures, so-called pathogen-associated molecular patterns. In addition to extracellular pattern recognition receptors (that is, TLRs), several intracellular pattern recognition receptors have been found to be responsible for the recognition of invading viruses in the cytoplasm. Retinoic acid-inducible protein 1 (RIG-1) is an interferon (IFN)-inducible proteincontaining caspase-activating and recruitment domains (CARDs) and an RNA helicase domain that functions as a cytoplasmic receptor for dsRNA (Yoneyama et al., 2004; Kato et al., 2005) . Melanoma differentiationassociated gene 5 (MDA5), a homologue of RIG-1, has also been suggested as a cytoplasmic receptor for dsRNA (Akira et al., 2006) .
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs, also called caterpillar) represent a large family of receptor proteins harboring an LRR domain for ligand sensing, an NOD and an initiating signal domain, such as CARD, PYRIN or baculovirus inhibitor of apoptosis repeat domains. These NLR proteins have been implicated in the recognition of bacterial components (Inohara et al., 2005; Martinon and Tschopp, 2005; Ting and Davis, 2005) . Activation of such cytoplasmic receptors by invading pathogens including bacteria and viruses leads to the production of proinflammatory cytokines such as IL-1b. Thus, TLRs, NLRs and RIG-1-like receptors (RLRs) are critical in bridging innate and adaptive immune responses. Although the roles of NLRs and RLRs in tumor immunity remain unclear, TLRs play a critical role in stimulating DC maturation, antigen uptake and presentation, and the differentiation of CD4 þ T cells (T helper (Th)1, Th2 and Th17) and controlling the suppressive function of regulatory T (Treg) cells. Thus, they represent a potent means of modulating immune responses to cancer vaccines, a novel strategy now being evaluated in clinical trials.
Ligand recognition and expression patterns
Since the discovery of TLRs, both natural and synthetic ligands for these receptors have been identified. TLR2 recognizes peptidoglycan found in gram-positive bacteria; TLR4 recognizes lipopolysaccharide, which is unique to  gram-negative bacteria; while TLR3, TLR7, TLR8, TLR9,  RIG-1 and MDA-5 recognize nucleic acids. TLR3  recognizes double-stranded RNA produced during viral  infection, and TLR9 recognizes an unmethylated cytosinephosphate-guanine (CpG) DNA motif of prokaryotic genomes and DNA viruses (Takeda and Akira, 2005) . TLR7 and 8 recognize single-stranded viral RNAs or guanosine-related analogs (loxoribine and imidazoquinoline) (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004) . Human TLR8 recognizes Poly-G3 oligonucleotides , while murine TLR8 is not functional (Jurk et al., 2002) . Unlike TLR2, 4, 5 and 6, which are expressed on the cell surface, TLR3, 7, 8 and 9 reside in endosomal compartments (Hemmi et al., 2002; Jurk et al., 2002; Akira and Takeda, 2004) . In particular, TLR7, 8 and 9 form an evolutionary cluster (Crozat and Beutler, 2004; Takeda and Akira, 2005) . Their endosomal localization is thought to be crucial for providing self versus non-self discrimination. For RNA sensing in the cytoplasm, RIG-I was recently shown to recognize the 5 0 end of certain viral RNA genomes, specifically, to uncapped 5 0 -triphosphate RNA (Hornung et al., 2006; Pichlmair et al., 2006) . Such 5 0 -triphosphates are generally removed or modified during post-transcriptional RNA processing of host RNA species, thereby remaining invisible or silent to innate immunity and providing a structural basis for the distinction of viral RNA from abundant self RNA in the cytoplasm of virally infected cells. TLR11 has been found to be inactive in humans, but is functional in mice and recognizes profilinlike molecule from the protozoan parasite Toxoplasma gondii (Zhang et al., 2004; Yarovinsky et al., 2005) .
Among the large number of NLR family members, NOD1 and NOD2 recognize bacteria-derived g-D-glutamyl-meso-diaminopimelic acid and muramyl dipeptide (MDP), respectively. Ligand binding to NOD1 and NOD2 induces their oligomerization and recruits RIP2/RICK to the complex, leading to activation of the nuclear factor (NF)-kB pathway and the production of inflammatory cytokines (Inohara et al., 2005; Martinon and Tschopp, 2005; Ting and Davis, 2005; Akira et al., 2006) . Recently, several groups demonstrated that NALP3 recognizes bacterial RNA, ATP and uric-acid crystals (Kanneganti et al., 2006; Mariathasan et al., 2006; Martinon et al., 2006; Sutterwala et al., 2006) . Specific ligands for other NOD-LRR family members remain to be identified.
Toll-like receptor expression has been detected on many types of cells, including different subsets of DCs, macrophages, T cells, neutrophils, eosinophils, mast cells, monocytes and epithelial cells (Iwasaki and Medzhitov, 2004) . Some TLRs have been reported to be expressed by T cells, such as Tregs Sutmuller et al., 2006b) .
Signaling pathways of TLRs and other innate immune receptors
The current model of TLR signaling pathways predicts that TLR1, 2, 5, 7, 8 and 9 use MyD88 as their sole receptor proximal adapter to transduce signals (Figure 1) . Thus, MyD88 is essential for the signaling of most TLRs to MyD88-IRKA4 and other downstream molecules. After the MyD88-IRAK4-IRAK1 complex activates TNFR-associated factor 6 (TRAF6), a ubiquitination protein ligase (E3), together with a ubiquitination E2 enzyme complex consisting of UBC13 and UEV1A, the TRAF6 complex catalyses the formation of a K63-linked polyubiquitin chain on TRAF6 itself and on NEMO, a subunit of IkB kinase (IKK) complex. Meanwhile, the recruitment of transforming growth factor (TGF)-bactivated kinase 1 (TAK1) and its binding proteins (TAB1, TAB2 and TAB33) leads to the phosphorylation of IKK-b and mitogen-activated protein (MAP) kinase 6 and then the activation of NF-kB and MAP kinase pathways for the production of inflammatory cytokines. Recent studies also suggest that MyD88 may also interact with IRF5 and 7 for the induction of proinflammatory cytokines or type-I IFN (IFN-a and IFN-b) response (Honda et al., 2005a, b; Takaoka et al., 2005) . TLR3 relies on a MyD88-independent, but TIR domaincontaining adaptor inducing IFN-beta (TRIF)-mediated pathway for the production of IFN-b in response to pathogen recognition, while TLR4 is linked to both MyD88-and TRIF-dependent pathways (Akira and Takeda, 2004; Takeda and Akira, 2005) . Activation of TLR3 leads to recruitment of receptor-interacting protein 1, TRAF3 and TRAF6, which activates TRAF family member-associated NF-kB activator-binding kinase 1 (TBK1) and/or inducible IkB kinase (IKK-i), which directly phosphorylate IRF3 and IRF7 for the production of type-I IFN cytokines (Akira et al., 2006) .
The adapter molecule IPS-1/MAVS/VISA/CARDIF of the RIG-1/MDA5 receptor for cytoplasmic dsRNA has been independently identified by several groups (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005b) . MAVS is present in the outer mitochondrial membrane, and the cleavage of this protein at the C terminus by NS3/4A protease of hepatitis C virus inactivates its ability to transduce signaling to TBK1 and IKK-i (Meylan et al., 2005; Seth et al., 2005; Lin et al., 2006) .
Activation of NALP3 recruits apoptosis-associated speck-like protein containing a CARD (ASC) through a homotypic interaction between the PYRIN domains. ASC then recruits caspase 1 via its CARD, leading to the activation of caspase-1 (Martinon and Tschopp, 2004 ). Active caspase-1 then cleaves pro-IL-1b for release from cells. It appears that TLR signaling is required for the production of pro-IL-1b. Hence, signaling via both TLRs and NLRs pathways is needed to achieve the maximal production of IL-1b (Mariathasan and Monack, 2007) .
Innate immunity links inflammation and cancer
Increasing evidence obtained with several different experimental approaches and tumor models supports the concept of cancer immunosurveillance (Dunn et al., 2004) . Innate immune cells including natural killer (NK), natural killer T (NKT) and gd T cells play a critical role in protecting the host against cancer (Dunn et al., 2004) . Macrophages and DCs, in particular, function as major sensors of invading pathogens and transformed cells via a limited number of germ lineencoded pattern recognition receptors such as TLRs. Adaptive immunity is crucial to the elimination of pathogens and tumor cells in the late phase of host defense responses and generates more specific tumor immunity and immunological memory. Several recent studies demonstrated that the recruitment of tumorinfiltrating immune cells, in particular CD8 þ T cells, is important correlate of patient survival (Zhang et al., 2003; Sato et al., 2005; Galon et al., 2006) , while the presence of other immune cells, such as Treg cells, is associated with a poor prognosis (Curiel et al., 2004) . These studies clearly demonstrate a role for innate and adaptive immunity in cancer immunosurveillance.
Paradoxically, activation of the innate immune response (in particular the NF-kB pathway) through TLR-mediated recognition of invading pathogens can also promote tumor development depending upon the cytokine milieu and the presence or absence of other immune cells (Greten et al., 2004; Karin and Greten, 2005) . For example, IL-1, IL-6, IL-8 and TGF-b released by immune cells and tumor cells promote angiogenesis, tumor growth and the differentiation of Th1, Th17 and Treg cells. Recent studies show that TLR and IL-1 receptor-associated kinases (IRAK) sequence polymorphism is an important risk factor for prostate cancer Xu et al., 2005a) . Chronic inflammation induced by Helicobacter pylori infection is the leading cause of stomach cancer, while inflammatory bowel diseases including ulcerative colitis and Crohn's disease are closely associated with colon cancer (Coussens and Werb, 2002; Karin et al., 2006) . Similarly, hepatitis B and C viral infections are the leading factor contributing to liver cancer (Coussens and Werb, 2002; Karin et al., 2006) . Recent studies clearly demonstrate that the MyD88-dependent signaling pathway has a critical role in the production of IL-6 and in both spontaneous and carcinogen-induced development of tumors (Naugler et al., 2007; Rakoff-Nahoum and Medzhitov, 2007) . Taken together, these studies indicate that TLRmediated inflammation from bacterial and viral infection can promote the development of cancers. Indeed, the blockade of signaling pathways required for inflammation or the induction of proinflammatory cytokines decreases the risk of tumorigenesis in model systems.
CD4
þ Th17 and Treg cells in cancer
Growing evidence suggests that CD4 þ Th cells play a central role in initiating and maintaining immune responses against cancer (Wang, 2001 ). Recent studies Figure 1 The signaling pathways of Toll-like receptors (TLRs) and RLRs. TLR2, TLR4 and TLR5 are expressed in the cell surface, while TLR3, TLR7, TLR8 and TLR9 are located in the endosomes. Retinoic acid-inducible protein 1 (RIG)-1 is a cytoplasmic receptor. TLR8 is functional in humans, but not functional in stimulating the nuclear factor (NF)-kB pathway in mice. The signaling pathways described are based on the data obtained from mice.
TLRs and immune regulation
þ Th effector cells are critical for the subsequent expansion of memory CD8 þ T cells (Janssen et al., 2003; Shedlock and Shen, 2003; Sun and Bevan, 2003) . In particular, CD4
þ Th cells are required during the maintenance phase of long-lived CD8 þ memory T cells (Sun et al., 2004) . Regulation of tumor-necrosis factor-related apoptosis-inducing ligand expression in CD8 þ T cells accounts for the role of CD4 þ T cells in the generation and expansion of memory and memory-like CD8 þ T cells (Janssen et al., 2005; Hamilton et al., 2006) þ T cells and critical help through the activation of DCs, which are essential in the priming of CD8 þ T-cell responses. Many TLR ligands or agonists promote Th1 cell development, whereas some TLR ligands such as helminthes promote the differentiation of CD4 þ Th2 cells. IL-4 produced by basophils, esinophils and NKT cells initiates Stat6 signaling, leading to expression of GATA-3, a master transcription factor in Th2 cells (Weaver et al., 2006) . Analysis of several hundreds of T-cell clones from tumor-infiltrating T cell lines established from melanoma patients revealed that over 95% of T cells are Th1 effectors, secreting IFN-g and IL-2, but not IL-4 or IL-13 (R-F Wang, unpublished data).
Th17 cells IL-17-producing T (Th17) cells are a distinct lineage within the general category of CD4
þ Th cells, secreting a unique set of cytokines IL-17 (Harrington et al., 2005; Park et al., 2005) . TGF-b and IL-6 produced by tumor cells, Treg cells and APCs activate TGF-b and Stat3 signaling pathways, leading to expression of RORgt, a critical transcription factor for Th17 cells (Ivanov et al., 2006) . Although Th17 cells are responsible for the pathogenesis of many autoimmune diseases, originally thought to be caused by self-reactive CD4 þ Th1 cells, their role in cancer is less clear. Nonetheless, both IL-17 and IL-23 have been identified in cancer tissues, suggesting that Th17 cells or proinflammatory cytokines may provide a tumor-promoting environment for cancer development or growth. We recently identified elevated percentages of Th17 cells in ovarian cancer tissues (R-F Wang, unpublished data).
Regulatory T cells CD4
þ Treg cells have been identified as a small subset (5-6%) of the overall CD4 þ T-cell population. Besides naturally occurring CD4 þ CD25 þ Treg cells, other CD4
þ Treg cells include Tr-1 cells secreting IFN-g and IL-10, and Th3 cells secreting high levels of TGF-b, IL-4 and IL-10 ( Roncarolo and Levings, 2000; Weiner, 2001; Francois Bach, 2003) . Foxp3 has proved to be a specific marker of CD4 þ Treg cells in both mice and humans (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003; Walker et al., 2003; Wang et al., 2004) . Its expression is highly restricted to the subset of Treg cells and correlates with immune suppressor activity, irrespective of CD25 expression (Fontenot et al., 2005; Wan and Flavell, 2005) . CD4
þ Treg cells can profoundly suppress host immune responses and induce self-tolerance (Roncarolo and Levings, 2000; Sakaguchi et al., 2001; Shevach, 2002) . Thus, despite their protective role in autoimmune diseases, these cells have inhibitory effects on cancer immunotherapy and infectious diseases (Shevach, 2000; Sakaguchi et al., 2001; Belkaid et al., 2002; Sakaguchi, 2004) . Recent studies demonstrated an elevated proportion of CD4 þ CD25 þ Treg cells in the total CD4 þ T-cell populations in several different human cancers, including lung, breast and ovarian tumors (Woo et al., 2001; Liyanage et al., 2002; Curiel et al., 2004) . In previous studies, we demonstrated the presence of antigenspecific CD4
þ Treg cells at tumor sites (Wang et al., 2004 , and showed that Treg cells suppressed the proliferation of naive CD4 þ T cells and inhibited IL-2 secretion of CD4 þ effector cells upon activation by tumor-specific antigens . Finally, we recently identified CD8 þ Treg as well as gd-TCR Treg cells in prostate and breast cancer Peng et al., 2007) . The former cells expressed Foxp3 molecules, while the latter did not. Like CD4 þ Treg cells, both of these Treg cell subtypes mediate immune suppression and inhibit antitumor immunity.
Control of differentiation of Th17 and Treg cells by TLR-stimulated cytokines
To determine the factors with critical roles in driving Th17 cell differentiation, several groups demonstrated that TGF-b and IL-6, but not IL-23, are essential for Th17 cell commitment (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006) , although IL-23 may still be required for survival and maintenance of Th17 cells in vivo. Because TGF-b is an important factor in the development and conversion of Treg cells, it may also influence the fate of CD4 þ T cells to become Treg cells or Th17 cells. The transcriptional factor for Treg cell development, Foxp3, is upregulated in the presence of TGF-b, but is inhibited by IL-6 through still poorly defined mechanisms. Several groups recently reported that IL-21 cooperates with TGF-b to promote Th17 cells and inhibit Treg cell differentiation (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007) , while retinoic acid is capable of inhibiting the IL-6-driven induction of proinflammatory Th17 cells and promoting antiinflammatory Treg differentiation (Mucida et al., 2007) .
Human Th17 cells were recently identified, but their regulation by cytokines differs from that in mice. For example, human Th17 cell differentiation requires IL-1b for differentiation, and IL-2, IL-6 and IL-23 for expansion of memory Th17 cells (Acosta-Rodriguez et al., 2007; Wilson et al., 2007) . Importantly, TGF-b, an essential factor for murine Th17 cell differentiation, actually inhibits human Th17 cell differentiation (Acosta- Rodriguez et al., 2007) . Despite the important role of Th17 in autoimmune diseases, its role in tumor development and progression is limited. One group recently reported that IL-23 promotes inflammatory responses and reduces CD8 þ T-cell responses (Langowski et al., 2006), while others claimed that DCs expressing IL-23 enhance antitumor immunity Yuan et al., 2006) . Hence, determining the subsets and prevalence of CD4 þ T cells in the tumor microenvironment could be critically important to improving therapeutic cancer vaccines. We recently demonstrated the presence of high percentages of human Th17 cells in ovarian cancer (R-F Wang, unpublished data). Moreover, ovarian tumor cells and tumor-associated fibroblasts secrete a large amount of IL-6, while tumor-associated APCs secrete large amounts of IL-1b and IL-6, both of which are critical for the differentiation and expansion of Th17 cells (R-F Wang, unpublished data). The cytokine milieu in the tumor microenvironment may be directly associated with TLR-mediated inflammation, thus determining whether CD4 þ T cells differentiate to Th1, Th2, Th17 and Treg cells. It appears that Th17 cell-mediated inflammation promotes tumor growth, while Treg cells inhibit antitumor immunity at tumor sites.
Functional control of Treg cell function by TLR signaling
To overcome immune suppression mediated by Treg cells, we screened cytokines and TLR ligands for their ability to reverse Treg-suppressive activity. We found that Poly-G10 oligonucleotides can directly reverse their suppressive function in the absence of DCs, depending upon a short stretch of guanosine oligonucleotides (2-10) (Figure 2 ). Using RNA interference technology, we showed that the TLR8-MyD88 signaling pathway is required for the reversal of Treg cell function by Poly-G oligonucleotides . Consistent with this result, we further showed that natural ligands for human TLR8, ssRNA40 and ssRNA33 derived from HIV viral sequences (Heil et al., 2004) completely reversed the suppressive function of Treg cells. These results suggest that binding and activation of TLR8 by either guanosine-containing DNA or RNA oligonucleotides is a key step in the reversal of Treg-suppressive function.
Importantly, we found that ligands for other human TLRs could not reverse the suppressive function of Treg cells, suggesting that TLR8 activation is specifically linked to regulation of Treg cell function (Figure 2 ). This finding is consistent with the data of another group showing that falgellin-mediated activation of TLR5 on human DCs and effector T cells leads to enhanced proliferation and IL-2 secretion by these cells (Crellin et al., 2005) . Stimulation of human Treg cells with flagellin increased rather than reversed their suppressive function (Crellin et al., 2005) . Interestingly, Poly-G oligonucleotides could not reverse the suppressive activity of murine Treg cells (since TLR8 is not functional in mice; Jurk et al., 2002) , although it is likely that other TLR ligands in mice affect Treg cell function and growth. Indeed, recent studies show that murine TLR2-deficient mice reduce the number of CD4 þ
CD25
þ Treg cells (Netea et al., 2004) . Activation of TLR2 with its ligand (Pam3Cys) directly increases the proliferation of murine Treg cells and transiently reverses their suppressive function (Sutmuller et al., 2006a) . However, since several studies reported that functional regulation of murine Treg cells is mainly achieved by TLR via DCs (Pasare and Medzhitov, 2003; Kubo et al., 2004; Fehervari and Sakaguchi, 2004) , further studies are needed to clarify this issue. Thus, the balance between murine Treg cell-suppressive function and naive/effector T-cell proliferation is controlled by TLRs through directly acting on Treg and effector T cells and indirectly acting on DCs (Figure 2) . Peng et al., 2007) , and showed that they also express a low level of human TLR8 molecules. One of the important questions is whether TLR8 ligands including Poly-G3 and ssRNA40 can reverse the suppressive function of CD8
þ Treg cells and gd-TCR Treg cells. Interestingly, we demonstrated that the suppressive function of CD8
þ Treg cells and gd-TCR Treg cells can be reversed after Poly-G oligonucleotide treatment, suggesting that these cells share a common TLR8 signaling-mediated mechanism with previously characterized CD4
þ Treg cell subsets. Further dissection of the downstream pathways of TLR8-MyD88 in shRNA knockdown experiments revealed that TRAF6, p38, IKKa and IKKb are required to enable Treg cells to respond to Poly-G3 treatment, while TAK1, JNK1 and extracellular signal-regulated kinase molecules are dispensable . These findings raise an intriguing possibility that manipulation of the TLR8 signaling pathway through its ligands or the use of drug inhibitors of key molecules in this pathway may allow one to block the suppressive function of different subsets of Treg cells, thus improving the efficacy of cancer vaccines.
Targeting TLRs for cancer therapy
Several TLR agonists have been developed as anticancer drugs. The TLR7 agonist imiquimod, for example, has been used to treat superficial basal cell carcinoma (Stockfleth et al., 2003) , while theTLR9 agonist CpG-ODN B type is being evaluated in clinical trials in patients with melanoma and lymphoma (Speiser et al., 2005; Jahrsdorfer et al., 2005a) . TLR4 agonists, including monophosphoryl lipid, have been used as adjuvant for vaccines against HBV and other pathogens (Baldridge et al., 2004) . Several mechanisms have been proposed to explain the apparent adjuvant effects of TLR agonists on antitumor immunity. First, TLRs trigger the secretion of critical cytokines such as IL1, IL-6 and IL-12 by DCs, which are important for T-cell differentiation and the induction of potent adaptive immunity. Several groups have shown that conjugation of certain TLR ligands (that is, for TLR2, TLR4, TLR7 and TLR9) to peptides or proteins significantly enhances CD4 þ and CD8 þ T-cell responses compared with administration of TLR ligands or a peptide/protein mixture alone (Jackson et al., 2004; Wille-Reece et al., 2005; Blander and Medzhitov, 2006) . Third, TLRs can directly stimulate the proliferation of CD4 þ and CD8 þ T cells as well as reverse the suppressive function of Treg cells (Crellin et al., 2005; Peng et al., 2005; Tabiasco et al., 2006) . Finally, TLR9 and TLR3 agonists may also induce apoptosis of TLR-expressing tumor cells (Jahrsdorfer et al., 2005b; Salaun et al., 2006) . However, as discussed above, optimal antitumor immunity requires robust enhancement of the effector T-cell response induced by tumor antigenic peptides and control or elimination of Treg cell-suppressive function. Thus, the combination of peptide-based vaccines with TLR agonists, in particular a TLR8 agonist, may greatly improve the therapeutic potential of cancer vaccines.
Conclusions and perspectives
Since their discovery a decade ago, TLRs have been shown to be critical for efficient innate and adaptive immunity and the framework of TLR-mediated signaling pathway has been elucidated. By contrast, the ligands recognized by NLRs and their signaling pathways remain to be determined. TLRs, NLRs and RLRs are clearly important in host response against infectious diseases and autoimmune diseases, the role of NLRs and RLRs in cancer immunosurveillance is much less certain. Increasing evidence indicates that immune suppression in the tumor microenvironment is a major obstacle to the development of effective therapeutic cancer vaccines. Tumor cells not only recruit Treg cells directly to tumor sites, but also help to convert naı¨ve and/or effector T cells into Treg cells by providing antigenic stimulation and cytokines directly or indirectly through tumor-infiltrating innate immune cells. TLRand NLR-dependent cytokine production by tumor cells, tumor-associated APCs and T cells is also critical in stimulating the differentiation of Th1, Th17 and Treg cells. The role of tumor-associated Th17 cells in cancer remains to be determined since inflammation has been linked to cancer. Recent studies from our own laboratory demonstrate that the suppressive function of different types of Treg cells can be reversed through the manipulation of TLR8 signaling; however, many questions remain to be addressed before the full clinical application of this observation is clear. For example, we are still uncertain as to why human TLR8 signaling can turn off the suppressive function of Treg cells, but other TLRs cannot, even though many of them use the same adapter molecules, such as MyD88 and IRAK4. Our most recent studies indicate that human TLR8 may use a unique signaling pathway to reverse Treg cell function. Thus, dissection of the TLR8-mediated signaling pathway and identification of the key molecules responsible for immune suppression are important challenges in the field. While many TLR agonists have been evaluated as anticancer drugs for cancer therapy, the therapeutic potential of reversing Treg cell function via TLR stimulation, either alone or in the combination with peptide-based vaccination, remains to be explored in the next few years.
